

Barcelona, February 17th 2021

OTHER RELEVANT INFORMATION

Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis

In accordance with Securities Markets Law approved Almirall, S.A. ("Almirall") announce the following:

MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora® Cream for treatment of plaque psoriasis. In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to significant sales milestone payments and double-digit royalties on the European sales. Almirall and MC2 Therapeutics partner to make Wynzora® Cream a leading topical product for treatment of plaque psoriasis in Europe - a market, which currently is more than 25 million units in sales volume annually. The market represents a significant opportunity as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of share of volume and annual sales of more than \$300 million.

Wynzora® Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th July 2020. The product is currently under review in Europe supported by two Phase 3 trials, including an EU head-to-head trial against active comparator Dovobet/Daivobet® Gel. Marketing Authorization Application (MAA) of Wynzora® Cream has been filed and approval is expected this year.

Wynzora® Cream was uniquely designed to provide patients a new treatment option in their daily routines by combining the three essentials of a topical therapy in one single product namely high efficacy, a favorable safety profile and convenience of use.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com